Neuro Prime
Natural health product licensed in Canada
- Other names
- Neuro Prime Brain
- Licence holder
- SellerX Germany GmbH & Co. KG
- NPN or DIN-HM
- 80123016
- Status
- Inactive licence
- Licence date
- 2 February 2023
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 2-(diméthylamino)éthanol Source : Bitartrate de déanol | 50 mg | Not calculated |
| [5R-(5alpha, 9beta, 11E)]-5-amino-11-éthylidène-5 ,6,9,10-tétrahydro-7-méthyl-5 ,9-méthane-cycloocta [b] pyridine-2 (1H)-one Source : Huperzia serrata - plante entière | 10 microgram | Not calculated |
| Phosphatidylsérine Source : Phosphatidylserine | 50 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 200 mg Potency : 24 % Flavonoid glycosides | 50 mg | Not calculated |
| Ginkgo biloba Source : Ginkgo biloba - feuille Potency : 6 % Terpene lactones | Not specified | Not calculated |
| Bacopa monnieri Source : Bacopa monnieri - Sommité (herbe) Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 1,200 mg Potency : 40 % Bacosides | 300 mg | Not calculated |
| Hypericum perforatum Source : Hypericum perforatum - herb top Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 2,600 mg | 130 mg | Not calculated |
| Sel interne de (2R)-2-(Acétyloxy)-3-carboxy-N,N,N-triméthyl-1-propanaminium Source : Dichlorhydrate d'arginate d'acétyle-L-carnitine | 50 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Hypromellose, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Hypericum perforatum is traditionally used in Herbal Medicine to help relieve restlessness and/or nervousness (calmative). Helps support cognitive health and/or brain function. Helps support memory.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80123016
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.